Selenium, CoQ10, and Two Clues to Cardiovascular Survival

Selenium status may have two biologically distinct windows: one into antioxidant enzyme activity and another into how well the body delivers selenium to its tissues. In an older Swedish population with low selenium intake, selenium plus CoQ10 raised both markers and was associated with lower cardiovascular mortality over 10 to 12 years. The more useful marker was selenoprotein P, or SELENOP. It also had an observational association with telomere length.

That is interesting biology, not a license to treat selenium as a universal cardiovascular supplement. The evidence comes largely from one 443-person trial in adults aged 69 to 88 with mean baseline serum selenium around 67 µg/L. Every active-treatment result reflects selenium yeast plus CoQ10, not selenium alone.

Two selenium markers answer different questions

Glutathione peroxidase-3 (GPx3) is an antioxidant enzyme. It is made mainly in the kidney and helps control oxidative damage outside cells. SELENOP is made in the liver and transports selenium to other tissues, including tissues that need selenium to make their own selenoproteins. SELENOP accounts for roughly 50% to 60% of selenium in serum; GPx3 accounts for about 10% to 15%.

The distinction matters because the two markers reached their modeled selenium plateaus at different concentrations in the KiSel-10 cohort. Alexander et al. (2025) estimated GPx3 saturation at about 99 µg/L serum selenium. Alehagen et al. (2024) estimated SELENOP saturation at about 146 µg/L. At a selenium level that appears sufficient by GPx3, selenium transport capacity may still be below its modeled maximum.

These are cohort-specific benchmark estimates, not validated clinical targets for everyone. They have not been independently replicated in another deficient elderly cohort within the available evidence.

What KiSel-10 actually tested

KiSel-10 randomly assigned 443 community-dwelling Swedish adults aged 69 to 88 to four years of selenium yeast, 200 µg per day, plus CoQ10, 200 mg per day, or matched placebo. Baseline serum selenium averaged about 67 µg/L, below both modeled saturation points. Subsequent biomarker analyses included somewhat smaller samples: 383 participants in the GPx3 analysis and 403 in the SELENOP analysis.

The active group had significantly higher GPx3 and SELENOP than the placebo group during the intervention. The studies also reported lower cardiovascular and all-cause mortality in association with the combined intervention over 10 to 12 years of follow-up. The supplied reports do not provide the relevant absolute risk differences, hazard ratios, confidence intervals, or biomarker effect sizes here, so those results cannot be sized precisely.

Randomization supports a causal inference about the four-year combined intervention and its biomarker changes. It does not identify which ingredient drove the changes. There was no selenium-only arm, no CoQ10-only arm, and no way to reconstruct either compound's separate contribution after the fact.

Why SELENOP looks more informative than GPx3

Both markers predicted cardiovascular mortality in KiSel-10 analyses, but SELENOP had better prognostic discrimination than GPx3 and raw serum selenium concentration. Higher SELENOP at follow-up tracked with lower 12-year cardiovascular mortality, while low baseline SELENOP tracked with worse survival.

GPx3 has a built-in interpretive problem in older adults: the kidney makes it. Alexander et al. reported that GPx3 falls as renal failure becomes more severe. Since kidney filtration commonly declines with age, a low GPx3 result can reflect reduced kidney function as well as selenium biology. That does not make GPx3 useless. It means a clinician should interpret it alongside renal function rather than treating it as a clean cardiovascular readout.

SELENOP avoids that particular renal confound because the liver secretes it. Its transport role also makes biological sense: selenium supports several redox-related proteins, including glutathione peroxidases and thioredoxin reductases. A 2024 mechanistic review by Angelone and colleagues describes how these selenoprotein systems help regulate cardiovascular redox signaling. Mechanistic plausibility explains why the finding deserves attention; it does not prove that raising SELENOP prevents heart disease.

The telomere result is a lead, not a longevity claim

Alehagen et al. also found that lower baseline SELENOP was associated with shorter telomere length at follow-up. Higher SELENOP correlated with lower inflammatory markers, better quality-of-life measures, and lower 12-year mortality.

The telomere result was not a prespecified randomized trial endpoint. It was an observational association within the same cohort. A shared cause could produce both lower SELENOP and shorter telomeres: illness, impaired liver synthetic capacity, inflammation, or another feature of accelerated aging. Reverse causation remains possible, and this evidence base contains no independent replication. Treat it as a reasonable research question, not evidence that selenium plus CoQ10 lengthens telomeres.

Why the Swedish findings may not travel

The strongest limitation is population specificity. KiSel-10 studied elderly Swedes with low baseline selenium in a region historically affected by selenium-poor soils and diets. It does not establish a benefit for younger adults, people with adequate selenium status, or people in countries where selenium intake is usually higher.

External evidence points in that direction, although it cannot settle the question. The 10-year observational ATTICA study found the selenium–cardiovascular disease relationship inconclusive in healthy Greek adults with moderate selenium status. A related 2024 ATTICA analysis linked GPx3 and SELENOP distributions with cardiovascular risk factors but did not report the clear mortality signal seen in KiSel-10.

Those studies differ from KiSel-10 in design, baseline selenium status, population, and endpoints. ATTICA was observational and involved generally healthier, non-deficient adults; KiSel-10 was a randomized combined-supplement trial in selenium-deficient older adults. The sensible conclusion is narrow: correcting deficiency may matter more than adding selenium above an already adequate level.

The broader selenium literature also contains major null-trial and systematic-review evidence in selenium-replete populations, including studies often cited in discussions of cardiovascular prevention. Those results are essential context, but they are not detailed enough in the available publications here to quantify responsibly. Their absence means this is not a complete estimate of selenium supplementation's overall cardiovascular effects.

What to do with this information

If a blood test shows selenium below roughly 100 µg/L, KiSel-10 offers a rationale to discuss selenium status and the trial's combined selenium-plus-CoQ10 regimen with a clinician, especially for an older person with a diet likely to be low in selenium. The trial tested 200 µg/day selenium yeast plus 200 mg/day CoQ10 for four years. It did not test a casual handful of selenium products, nor did it prove that selenium alone produced the outcomes.

If selenium is already above about 100 µg/L, these data do not establish a cardiovascular reason to supplement. GPx3 was already at its modeled plateau near that concentration in KiSel-10, and ATTICA found no clear cardiovascular benefit signal in adults with moderate selenium status.

SELENOP is the more informative research biomarker in this story, while GPx3 requires kidney-function context. The most defensible reading of KiSel-10 is also the least glamorous: in selenium-deficient older adults, selenium plus CoQ10 changed biologically relevant markers and coincided with better long-term survival. Whether that result belongs to selenium, CoQ10, their interaction, or this particular population remains unresolved.

Bottom line: Do not use the telomere association as an anti-aging sales pitch. Use the trial as evidence that selenium deficiency is worth identifying—and that the tested intervention was selenium plus CoQ10, not selenium in isolation.

Sources

• Alexander et al. (2025), GPx3, renal function, and cardiovascular mortality
• Alehagen et al. (2024), SELENOP, telomeres, inflammation, and mortality
• Alehagen et al. (2023), age-related biomarkers in KiSel-10
• Angelone et al. (2024), selenoproteins in cardiovascular redox biology
• Detopoulou et al. (2023), the ATTICA study